SynthesisNeurosurgical review2021
Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review.
Synthesis in Neurosurgical review, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review.Journal of neuro-oncology · 2023Pooled it
- MGMT promoter methylation modulates the effect of residual tumor on survival after re-resection of recurrent glioblastoma.Acta neuropathologica communications · 2026Article
- The effect of tumor growth kinetics on survival and time toxicity after resection of recurrent glioblastoma.Neurosurgical focus · 2025Article
- Glioblastoma in NF1: A Unique Entity-A Literature Review Focusing on Surgical Implication and Our Experience.Current oncology (Toronto, Ont.) · 2025Review
- Second surgery for relapsed glioblastoma: an observational study on criteria for patient selection in real life.Future oncology (London, England) · 2024Observational
- Novel Iron-Chelating Prodrug Significantly Enhanced Fluorescence-Mediated Detection of Glioma Cells Experimentally In Vitro.Pharmaceutics · 2023Article
- Added value of [European journal of nuclear medicine and molecular imaging · 2023Article
- Management of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?Cancers · 2022Article
- Review
- Predictors and Impact of Postoperative 30-Day Readmission in Glioblastoma.Neurosurgery · 2022Article
- A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications.Frontiers in oncology · 2022Article
- Current status and recent advances in reirradiation of glioblastoma.Radiation oncology (London, England) · 2021Review
- C-methionine-PET-guided Gamma Knife radiosurgery boost as adjuvant treatment for newly diagnosed glioblastomas.Surgical neurology international · 2021Article
- Fluorescence-Guided High-Grade Glioma Surgery More Than Four Hours After 5-Aminolevulinic Acid Administration.Frontiers in neurology · 2021Article
- Article
- A Phase 1 Dose-Escalation Trial of Reirradiation for Patients With Recurrent Glioblastoma.Practical radiation oncologyArticle
- Value-based assessment of repeat surgery for recurrent glioma: A real-world quality-adjusted survival analysis.Neuro-oncology advancesArticle
- GammaTile® brachytherapy in the treatment of recurrent glioblastomas.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe inevitable recurrence of glioblastoma (GBM) results in patients often undergoing multiple resections with questionable benefit to overall survival (OS).
objectiveTo systematically review and analyze prior studies examining the potential added benefit of repeat resection (RR) in recurrent GBM.
methodsWe performed a PRISMA-compliant systematic review of literature published between 1969 to 2019 involving patients undergoing RR at GBM recurrence.
resultsThe search yielded 3994 non-duplicate citations. Final abstraction included 43 articles, with 2 level II and 41 level III studies. The earliest paper we included was published in 1987 [1], and 35 identified papers (81.4%) were published within the last 10 years. The survival data of 9236 patients (55% male) were analyzed, with a median age of 56; 3726 patients underwent RR. In 31 studies with a comparable single-surgery-only cohort, 20 articles reported a statistically significant increase in OS with RR, 7 reported nonsignificant trends toward increased OS with RR, and 4 reported no significant increase in OS with RR. Twenty-two articles with multivariate analyses of Karnofsky performance scores and 17 articles with extent-of-resection reported these as significant prognostic factors of OS. In 26 studies, median OS among all patients was 17.85 months inclusive of median OS following RR totaling 9.6 months. Notably, in 10 studies with data on subsequent progressions (2+ recurrences), 6 studies reported significant increases in OS with subsequent repeat resection (sRR) compared to those not undergoing sRR.
conclusionsRecurrent GBM presents a treatment challenge. There appears to be an OS benefit for RR upon first recurrence as well as sRR. Such findings warrant further investigation of the potential benefits of continued surgical intervention after subsequent progressions of GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.